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Background
Acute viral bronchiolitis is one of the most common
respiratory infections in infancy, leading to the hospitaliza-
tion of about 1-2% of infected infants. A number of studies
have suggested that hospitalization due to bronchiolitis
could increased the risk of developing pulmonary sequelae,
specially recurrent cough and wheezing.
Methods
This is a randomized, pilot study, involving infants ≤ 1
year of age hospitalized due to acute viral bronchiolitis.
All patients with moderate-severe bronchiolitis (Wang
score ≥ 8) are eligible to initiate the study. At hospital
discharge, recruited patients are randomized into three
study groups - conventional treatment, oral montelukast
(MK) or inhaled beclomethasone dipropionate (BDP) -
and directed to monthly follow-up appointments for
6 months. We aim to determine the potential benefit of
inhaled BDP and oral MK in the natural history of post
bronchiolitis wheezing. The primary variables are: need
of hospitalization and number of visits to the emergency
department (ED). The secondary variables are: number
of days until first exacerbation, duration of hospitaliza-
tion, number of asymptomatic days and need of bronch-
odilator and/or oral corticosteroid.
Results
Until this moment, 47 patients were randomized, out of
which, 26 ended the study, being 9 in the no treatment
group(A), 11 in the oral MK group (B) and 6 in the
inhaled BDP group (C). Considering the primary variables,
only one hospitalization was reported in the no treatment
group A. Among group A, 3 visits to the ED were reported
and 5 infants needed to use albuterol spray (1-3 times); 1
patient was excluded. Among the 11 patients in the oral
MK group B, 2 infants developed a wheezing episode fol-
lowing a viral respiratory infection, 2 visits to the ED were
reported and 4 infants needed to use albuterol spray (1-2
times); 2 patients were excluded. Among the 6 patients in
the inhaled BDP group C, 2 infants needed to use albu-
terol spray (1-3 times); 2 patients were excluded.
Conclusions
To the extent of our knowledge, there are no studies
comparing inhaled BDP and oral MK in the prophylaxis
of post acute viral bronchiolitis wheezing. A larger num-
ber of patients will allow us to establish more significant
statistical data. More studies are necessary to establish
the presumable benefit of MK and/or inhaled BDP in
the history of post bronchiolitis recurrent wheezing.
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